When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Opioid use disorder

Evidencia revisada por última vez: 2 Oct 2026
Tema actualizado por última vez: 21 Jul 2026

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • maladaptive pattern of opioid use
  • high Addiction Severity Index (ASI) score
  • blunting of pleasurable opioid effects
  • miosis
  • dilated pupils
  • shallow/slow respirations or apnea
  • needle marks, scars, or necrosis on skin near veins
  • unconsciousness
  • pulse <40 bpm
Todos los datos

Otros factores de diagnóstico

  • chronic constipation
  • weight loss
  • nausea/vomiting
  • sedation
  • restless sleep/insomnia
  • memory impairment
  • sneezing
  • yawning
  • abdominal cramps
  • diarrhea
  • backache/muscle spasms
  • hot and cold flashes
  • hypotension
  • sedation
  • confusion
  • slurred speech
  • aggressive behavior
  • excess perspiration or lacrimation
  • rhinorrhea
  • restlessness
  • piloerection
  • tachypnea
  • hypertension
  • arrhythmias
  • seizures
Todos los datos

Factores de riesgo

  • young age at substance use initiation
  • history of a mental health disorder
  • history of substance use
  • long-term opioid therapy
  • childhood trauma
  • homelessness/housing instability
  • family history of substance use
  • criminal justice system involvement
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • Addiction Severity Index (ASI)
  • clinical opiate withdrawal scale (COWS)
  • urine or saliva drug screen
  • gas chromatography-mass spectroscopy (GC-MS)
  • serum electrolytes
  • CBC
  • BUN/creatinine
  • LFTs
  • hepatitis serology
  • HIV serology
  • purified protein derivative (PPD) skin test
Todos los datos

Pruebas diagnósticas que deben considerarse

  • rapid plasma reagin
  • blood cultures
  • beta human chorionic gonadotropin (beta-hCG)
Todos los datos

Algoritmo de tratamiento

Agudo

nonpregnant adults in inpatient/outpatient medically supervised withdrawal program

nonpregnant adolescents in inpatient/outpatient medically supervised withdrawal program

pregnant women in inpatient/outpatient medically supervised withdrawal program

nonpregnant adults after medically supervised withdrawal or suitable for initial or early maintenance therapy

nonpregnant adolescents after medically supervised withdrawal or suitable for initial or early maintenance therapy

pregnant women after medically supervised withdrawal or suitable for initial or early maintenance therapy

Colaboradores

Autores

Ashwin A. Patkar, MD, MRCPsych

Associate Professor

Medical Director

Duke Addictions Program

Department of Psychiatry and Behavioral Sciences

Duke University Medical Center

Durham

NC

Divulgaciones

AAP is a stockholder in Generys Biopharmaceuticals that has compounds in development for drug addiction (for stimulant use disorder). AAP provides expert testimony for United States Federal Agencies and is an expert reviewer for North Carolina Medical Board.

Jonathan C. Lee, MD

Medical Director

The Farley Center at Williamsburg Place

Williamsburg

Community Assistant Professor

Department of Family Medicine

Eastern Virginia Medical School

Norfolk

Assistant Clinical Professor

Department of Psychiatry

Virginia Commonwealth University

Richmond

VA

Affiliate Assistant Professor

Department of Psychiatric Medicine

East Carolina University

Greenville

NC

Divulgaciones

JCL declares that he has no competing interests.

Agradecimientos

Dr Ashwin A. Patkar and Dr Jonathan C. Lee would like to gratefully acknowledge Dr Douglas M. Burgess, Dr Kamal Bhatia and Dr Srilakshmi Musham, previous contributors to this topic.

They would also like to thank Isabel Patton, who assisted with the 2025 scheduled update.

Divulgaciones

DMB declares that he has no competing interests. KB declares that he has received grant support from National Institutes of Health, Lundbeck, Pfizer, and Titan Pharmaceuticals. SM declares that she has received grant support from Pfizer, Titan Pharmaceuticals, Shire, and the Forest Research Institute. IP declares being an employee of AAP who has declared interests above. IP has coauthored a manuscript with AAP.

Revisores por pares

Christos Kouimtsidis, MBBS, MSc, MRCPsych, PhD

Consultant Psychiatrist and Honorary Senior Lecturer

Institute of Psychiatry

King's College London

London

UK

Divulgaciones

CK declares that he has no competing interests.

George E. Woody, MD

Emeritus Professor

Department of Psychiatry

Perelman School of Medicine

University of Pennsylvania

Philadelphia

PA

Divulgaciones

GEW declares that he has no competing interests. GEW is an author of a number of references cited in this topic.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.Texto completo

World Health Organization. WHO releases 2025 update to the International Classification of Diseases (ICD-11). Feb 2025 [Internet publication].Texto completo

American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. 2020 Mar/Apr;14(2S suppl 1):1-91.Texto completo  Resumen

Substance Abuse and Mental Health Services Administration. TIP 63: medications for opioid use disorder. Jul 2021 [internet publication].Texto completo

National Institute for Health and Care Excellence. Drug misuse in over 16s: opioid detoxification. Jul 2007 (reaffirmed 2019) [internet publication].Texto completo

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Opioid use disorder images
  • Diferenciales

    • Alcohol intoxication
    • Sedative intoxication
    • Anticholinergic intoxication
    Más Diferenciales
  • Guías de práctica clínica

    • Clinical practice guideline: assessment and treatment of adolescents and young adults with substance use disorders and problematic substance use (excluding tobacco)
    • Management of opioid use disorder: 2024 update to the national clinical practice guideline
    Más Guías de práctica clínica
  • Folletos para el paciente

    Opioid-use disorder

    Más Folletos para el paciente
  • Calculadoras

    Clinical Opioid Withdrawal Scale (COWS) for adults and adolescents

    Más Calculadoras
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad